Hermetica Superfood Encyclopedia
The Short Answer
Aurantio-obtusin is a naturally occurring anthraquinone compound isolated primarily from Cassia obtusifolia (sickle senna) seeds. It exerts its primary effects through modulation of PPAR nuclear receptors, aldose reductase inhibition, and activation of insulin signaling cascades, making it a subject of interest in metabolic health research.
CategoryNamed Bioactive Compounds
GroupCompound
Evidence LevelModerate
Primary Keywordaurantio-obtusin benefits
Synergy Pairings3
Aurantio-obtusin — botanical close-up
Health Benefits
Origin & History
Natural habitat
Aurantio-obtusin is an anthraquinone monomer compound extracted from the seeds of Cassia species, primarily Senna obtusifolia and Senna tora. It serves as the primary bioactive component and quality control index in the Pharmacopoeia of the People's Republic of China, requiring not less than 0.080% on a dried basis.
“Cassia seeds containing aurantio-obtusin have been used in Traditional Chinese Medicine for centuries to treat obesity, diabetes, non-alcoholic fatty liver disease, and allergic reactions. The compound serves as the modern quality marker for this traditional remedy in Chinese pharmacopoeia.”Traditional Medicine
Scientific Research
No human clinical trials, randomized controlled trials, or meta-analyses have been conducted on aurantio-obtusin. All available evidence comes from preclinical studies including in vitro assays and animal models examining effects on hyperlipidemia, obesity, diabetes complications, and fatty liver.
Preparation & Dosage
Traditional preparation
No clinically studied dosage ranges are available as no human trials have been conducted. Chinese pharmacopoeia standardizes Cassia seed extracts to contain at least 0.080% aurantio-obtusin on a dried basis. Consult a healthcare provider before starting any new supplement.
Nutritional Profile
Aurantio-obtusin is a purified bioactive anthraquinone compound (molecular formula C17H14O8, molecular weight 350.28 g/mol), not a whole food or nutritional source, and therefore does not contain macronutrients, dietary fiber, or conventional micronutrients. It is not a source of protein, carbohydrates, or fats in any nutritional context. As a secondary plant metabolite isolated primarily from Cassia obtusifolia (Jue Ming Zi/Semen Cassiae) seeds, its relevance is pharmacological rather than nutritional. Bioactive compound profile: Aurantio-obtusin itself is the primary active constituent of interest, typically present in Cassia obtusifolia seeds at concentrations ranging from approximately 0.1–0.5 mg/g dry weight depending on extraction method and plant source. It belongs to the anthraquinone glycoside/aglycone class. Key functional chemistry includes hydroxyl and methoxy substituents at positions 1, 2, 3, 6, and 8 of the anthraquinone backbone, contributing to its bioactivity. Bioavailability notes: Oral bioavailability data in humans is not established; preclinical pharmacokinetic data suggests moderate intestinal absorption with hepatic first-pass metabolism likely significant. Lipophilicity (estimated LogP ~1.8–2.5) suggests passive membrane permeability. No recommended dietary intake or tolerable upper limit has been established for this isolated compound.
How It Works
Mechanism of Action
Aurantio-obtusin modulates lipid metabolism by upregulating peroxisome proliferator-activated receptor alpha (PPAR-α) while downregulating PPAR-γ expression in hepatic tissue, shifting the balance toward fatty acid oxidation over lipid storage. It inhibits aldose reductase with an IC50 of 13.6 µM, reducing the conversion of glucose to sorbitol via the polyol pathway, which is implicated in diabetic complications. Additionally, it activates downstream insulin signaling components including PI3K/Akt and AMPK pathways, potentially enhancing glucose uptake and utilization in peripheral tissues.
Clinical Evidence
The majority of evidence supporting aurantio-obtusin is derived from in vitro cell-based assays and rodent models, with no published randomized controlled human clinical trials as of current literature. Animal studies using streptozotocin-induced diabetic mouse models have demonstrated reductions in fasting blood glucose and improvements in lipid panels at oral doses typically ranging from 10–50 mg/kg body weight. Preclinical cardiovascular studies suggest vasodilatory and anti-inflammatory effects, potentially mediated through NF-κB pathway suppression, though effect sizes and translational relevance to humans remain unestablished. The overall evidence base is early-stage and preclinical; human pharmacokinetic and efficacy data are largely absent.
Safety & Interactions
Aurantio-obtusin has not been evaluated in formal human safety or toxicology trials, and its safety profile in humans is not well characterized. As an anthraquinone derivative, it shares structural similarities with compounds like emodin and aloe-emodin that have demonstrated potential genotoxicity in high-dose in vitro studies, warranting caution. It may interact with antidiabetic medications such as metformin or insulin secretagogues due to additive blood glucose-lowering effects, and co-administration with lipid-lowering drugs like statins or fibrates requires theoretical caution due to overlapping PPAR-α mechanisms. Use during pregnancy and lactation is not recommended due to the complete absence of safety data, and individuals with hepatic or renal impairment should avoid supplementation without medical supervision.
Synergy Stack
Hermetica Formulation Heuristic
Frequently Asked Questions
What plant does aurantio-obtusin come from?
Aurantio-obtusin is primarily isolated from the seeds of Cassia obtusifolia, commonly called sickle senna or jue ming zi in traditional Chinese medicine. It is also found in smaller concentrations in related Cassia species such as Cassia tora. The seeds have historically been used in East Asian herbal medicine for eye health and constipation.
Can aurantio-obtusin lower blood sugar?
Preclinical animal studies suggest aurantio-obtusin may support blood sugar regulation through two mechanisms: inhibition of aldose reductase (IC50 of 13.6 µM), which reduces glucose flux through the polyol pathway, and activation of the PI3K/Akt insulin signaling cascade in peripheral tissues. However, no human clinical trials have confirmed these effects, so blood sugar-lowering claims cannot currently be substantiated for human use. Individuals on diabetes medications should not substitute or combine aurantio-obtusin without physician guidance.
How does aurantio-obtusin affect cholesterol and lipids?
In rodent models of hyperlipidemia, aurantio-obtusin has been shown to reduce total cholesterol, LDL cholesterol, and triglycerides while modestly increasing HDL cholesterol. The proposed mechanism involves increasing hepatic PPAR-α expression, which promotes fatty acid beta-oxidation, while simultaneously reducing PPAR-γ activity, which limits lipid accumulation in the liver. These results are promising but confined to animal studies at doses of approximately 10–50 mg/kg, and human equivalence has not been established.
Is aurantio-obtusin safe to take as a supplement?
Human safety data for isolated aurantio-obtusin does not currently exist in peer-reviewed literature. As an anthraquinone, it belongs to a chemical class that includes compounds with potential genotoxic and hepatotoxic effects at high doses, as demonstrated in in vitro studies with structurally related molecules like emodin. Until formal Phase I human trials establish a safe dosage range and toxicological profile, aurantio-obtusin supplements should be approached with significant caution, particularly for long-term use.
What is the difference between aurantio-obtusin and emodin?
Both aurantio-obtusin and emodin are anthraquinone compounds found in Cassia species, but they differ in their hydroxyl and methoxy substitution patterns on the anthraquinone backbone, giving them distinct pharmacological profiles. Emodin is more extensively studied and is associated with laxative effects, anti-inflammatory activity, and notable in vitro genotoxicity concerns, while aurantio-obtusin research is concentrated on metabolic effects including PPAR modulation and aldose reductase inhibition. Their overlapping structural features mean similar safety cautions may apply, but they should not be considered pharmacologically interchangeable.
What does the research quality show about aurantio-obtusin's cardiovascular effects?
Most cardiovascular evidence for aurantio-obtusin comes from in vitro and animal studies demonstrating activation of the PI3K/Akt/eNOS pathway for vasodilation, but human clinical trials are limited or absent. While these mechanistic findings are promising, the gap between laboratory evidence and real-world efficacy in humans remains significant. More randomized controlled trials are needed to establish clinically meaningful cardiovascular benefits in supplement users.
Who would most benefit from aurantio-obtusin supplementation based on current research?
Individuals interested in metabolic support, particularly those concerned with blood sugar regulation or lipid metabolism, may find aurantio-obtusin relevant based on animal and preclinical data. However, because human clinical evidence is limited, it is not yet possible to identify specific populations who would definitively benefit. Anyone considering this ingredient should consult a healthcare provider to determine suitability for their personal health goals.
How does bioavailability affect aurantio-obtusin's effectiveness as a supplement?
Aurantio-obtusin's effectiveness depends heavily on absorption and bioavailability, which can be influenced by the supplement form, digestive pH, and presence of other compounds in food or formulations. Most published IC50 and pathway activation data derive from in vitro or animal models where bioavailability may differ significantly from oral human supplementation. The actual dose reaching target tissues in humans remains poorly characterized, potentially limiting real-world efficacy compared to laboratory results.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w aurantio-obtusin curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
